Quality of life of metastatic renal carcinoma patients receiving subcutaneous interferon or intravenous interleukin-2

Trends in Kidney Cancer Research

Volumn 18, Issue , 2006, Pages 103-118

  Négrier, Sylvie ^a   Touzet, Sandrine ^a   Gomez, Frédéric ^a   Douillard, Jean Yves ^b   Ravaud, Alain ^c   Chevreau, Christine ^d   Dazord, Alice ^e   Escudier, Bernard ^f  

^a CENTRE LÉON BÉRARD   (France)

^b Centre Gauducheau Medicine Oncologie   (France)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e Hopital Saint Jean de Dieu   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cytokine; Interferon; Interleukin 2; Quality of life; Renal carcinoma

Indexed keywords

EID: 84895377363     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (25)

1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 335: 865, 1996.
2. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310, 1988.
3. Pyrhönnen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 859, 1999.
4. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228: 307, 1998.
5. Fyfe GA, Fisher RI, Rosenberg SA Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with highdose recombinant interleukin-2. J Clin Oncol 14: 2410, 1996.
6. Négrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 6: S93, 2000.
7. Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272, 1998.
8. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14, 1999.
9. Heinzer H, Mir TS, Huland E, Huland H. Subjective and objective prospective, longterm analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17: 3612, 1999.
10. Kroger MJ, Menzel T, Gschwend JE, Bergmann L. Life quality of patients with metastatic renal cell carcinoma chemo-immunotherapy, a pilot study. Anticancer Res 19: 1553, 1999.
11. Litwin MS, Fine JT, Dorey F Figlin RA, Belldegrun AS. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. J Urol 157: 1608, 1997.
12. Wong M, Goldstein D, Woo H, Testa G, Gurney H. Alpha-interferon 2a and 13-cisretinoic acid for the treatment of metastatic renal cell carcinoma. Intern Med 32:158, 2002.
13. Cohen L, de Moor C, Parker PA, Amato RJ. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol 7:119, 2002.
14. Motzer RJ, Murphy JA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972, 2000.
15. Gerin P, Dazord A, Boissel J, Chifflet R. Quality of life assessment in therapeutic trials: rationale for and presentation of a more appropriate instrument. Fundam Clin Pharmacol. 1992;6(6):263-76.
16. Dazord A. Quality of life assessment in medicine. Presentation of a new instrument (SQLP: subjective quality of life profile) and first results. Eur Respirat Rev 5: 66, 1995.
17. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Validation of the United States' version of the World Health Organization Quality of Life (WHOQOL) instrument. J Clin Epidemiol. 2000 Jan; 53(1): 1-12.
18. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300: 1458, 1990.
19. Olver IN, Matthews JP, Bishop JF, Smith RA. The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 30A: 1223, 1994.
20. Bjordal K, Freng A, Thorvik J, Kaasa S. Patient self-reported and clinician rated quality of life in head and neck cancer patients; a cross sectional study. Eur J Cancer 31B: 340, 1995.
21. Kahn SB, Houts PS, Harding SP. Quality of life and patients with cancer: A comparative study of patients versus physicians perceptions and its implications for cancer education. J Cancer Educ 7: 241, 1992.
22. Osoba D. Lessons learned from measuring health-related quality of life in Oncology. J Clin Oncol 12: 608, 1994.
23. Waldron D, O'Boyle C, Kearney M, Moriarty M, Carney D. Quality of life measurement in advanced cancer: assessing the individual. J Clin Oncol 17: 3603, 1999.
24. Schipper H, Clinch J, Powell V. Definition and conceptual issues. Quality of life assessments in clinical trials. B. Spilker Ed. Raven Press Ltd. New York, 1990.
25. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.